-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $106

Benzinga·11/04/2026 12:26:20
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $106.